188 related articles for article (PubMed ID: 28299752)
1. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
3. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
Kondo T; Kanai M; Matsubara J; Quy PN; Fukuyama K; Yamamoto Y; Yamada T; Nishigaki M; Minamiguchi S; Takeda M; Nishio K; Matsumoto S; Muto M
Pancreas; 2020; 49(10):e101-e103. PubMed ID: 33017331
[No Abstract] [Full Text] [Related]
4. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract][Full Text] [Related]
6. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic.
Rodríguez Gil Y; Jiménez Sánchez P; Muñoz Velasco R; García García A; Sánchez-Arévalo Lobo VJ
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669845
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnostics of hepatobiliary and pancreatic neoplasias.
Longerich T; Stenzinger A; Schirmacher P
Virchows Arch; 2024 Feb; 484(2):263-272. PubMed ID: 38429607
[TBL] [Abstract][Full Text] [Related]
8. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.
Casolino R; Braconi C; Malleo G; Paiella S; Bassi C; Milella M; Dreyer SB; Froeling FEM; Chang DK; Biankin AV; Golan T
Ann Oncol; 2021 Feb; 32(2):183-196. PubMed ID: 33248227
[TBL] [Abstract][Full Text] [Related]
9. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
10. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
Chang JC; Kundranda M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
[TBL] [Abstract][Full Text] [Related]
11. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
[No Abstract] [Full Text] [Related]
12.
Kim G
Cancer Manag Res; 2017; 9():85-96. PubMed ID: 28356771
[TBL] [Abstract][Full Text] [Related]
13. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
[TBL] [Abstract][Full Text] [Related]
14. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
Manji GA; Olive KP; Saenger YM; Oberstein P
Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome analysis of pancreatic cells across distant species highlights novel important regulator genes.
Tarifeño-Saldivia E; Lavergne A; Bernard A; Padamata K; Bergemann D; Voz ML; Manfroid I; Peers B
BMC Biol; 2017 Mar; 15(1):21. PubMed ID: 28327131
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.
Syren P; Andersson R; Bauden M; Ansari D
Scand J Gastroenterol; 2017; 52(6-7):668-673. PubMed ID: 28301276
[TBL] [Abstract][Full Text] [Related]
17. Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
Ottaiano A; Capozzi M; DE Divitiis C; VON Arx C; DI Girolamo E; Nasti G; Cavalcanti E; Tatangelo F; Romano G; Avallone A; Tafuto S
Anticancer Res; 2017 Apr; 37(4):1975-1978. PubMed ID: 28373469
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
[TBL] [Abstract][Full Text] [Related]
20. Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic.
Du Y; Zhao B; Liu Z; Ren X; Zhao W; Li Z; You L; Zhao Y
J Cancer; 2017; 8(4):513-522. PubMed ID: 28367231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
